Extended Data Fig. 1: Weight loss effect of semaglutide on MASH resolution (a), steatosis improvement (b), hepatocyte ballooning (c) and liver fibrosis improvement (d).
Data based on complete-case on-treatment measurements. Scatter points show responder rates for five weight-loss categories. Enlarged data points show the overall mean body-weight loss versus overall responder rate. Outcome model: logistic regression at week 72. Mediators: weight loss at weeks 4, 12, 20, 28, 36, 44, 52, 62 and 72. Baseline confounders: age, gender, type 2 diabetes status, fibrosis stage and body weight. MASH, metabolic dysfunction-associated steatohepatitis; WL, weight loss.
